Sarepta therapeutics executes licensing agreement for gene therapy program from nationwide children's hospital to treat limb-girdle muscular dystrophy type 2a

–  limb-girdle muscular dystrophy type 2a is the most common form of lgmd, accounting for a third of lgmd diagnoses
SRPT Ratings Summary
SRPT Quant Ranking